NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

毛細胞白血病的全球市場(2021年∼2028年)

Global Hairy Cell Leukemia Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008254
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
毛細胞白血病的全球市場(2021年∼2028年) Global Hairy Cell Leukemia Market - 2021-2028
出版日期: 2021年05月27日內容資訊: 英文 180 Pages
簡介

毛細胞白血病市場成長的主要因素有老年人群快速增長,隨著診斷技術的提高和加速,毛細胞白血病的治療人數將會增加。在過去的20年中,毛細胞白血病的診斷率有所增加,預計將在預測期內推動市場。但是,由於對毛細胞白血病認識不足,以及在治療方面缺乏研究和開發新療法的努力,預計在預測期內將阻礙市場。

本報告提供全球毛細胞白血病市場的相關調查,提供市場機會和影響,成長及阻礙因素,療法·終端用戶·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球毛細胞白血病市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球毛細胞白血病市場-市場定義和概要

第3章 全球毛細胞白血病市場-摘要整理

  • 各療法市場明細
  • 各終端用戶市場明細
  • 各地區的市場明細

第4章 全球毛細胞白血病市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球毛細胞白血病市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球毛細胞白血病市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 當前的 COVID-19 市場情景
    • COVID-19後的市場方案或未來情景
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 疫情期間與市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球毛細胞白血病市場-各療法

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 標靶治療
    • 簡介
    • 市場規模分析(2018-2028)及與前一年同期比較成長分析(2020-2028)
  • 免疫療法
  • 放射治療
  • 化療

第8章 全球毛細胞白血病市場-各終端用戶

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 醫院
    • 簡介
    • 市場規模分析(2018-2028)及與前一年同期比較成長分析(2020-2028)
  • 診所
  • 門診病人手術中心

第9章 全球毛細胞白血病市場-各地區

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要每個地區的動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要每個地區的動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要每個地區的動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要每個地區的動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要每個地區的動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析

第10章 全球毛細胞白血病市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第11章 全球毛細胞白血病市場-企業簡介概要

  • Amgen Inc.
    • 企業概要
    • 產品系列·概要
    • 要點
    • 財務概要
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • UCB SA

第12章 全球毛細胞白血病市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global hairy cell leukemia market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Hairy cell leukemia is a rare type of cancer, which accounts for approximately 2% of all leukemia. Hairy cell leukemia is described by the uncontrolled growth of lymphocytes by the bone marrow. Hairy cell leukemia got its unique name from a morphology trait it displays. The excess B cells in hairy cell leukemia increase abnormal extensions and look hairy. With the rise in the number of leukemia cells, the amount of healthy white blood cells, red blood cells, and platelets in the body reduce significantly.

The risk factors for hairy cell leukemia treatment involve extended radiation exposure and certain agricultural and industrial chemicals. People of Ashkenazi Jewish ethnicity are also more susceptive to hairy cell leukemia than other groups. The diagnostic approached to distinguish hairy cell leukemia treatment include physical examination for increased spleen and lymph nodes, bone marrow biopsy, blood tests, imaging studies such as CT scan and tumor maker presence test.

Market Dynamics

The hairy cell leukemia market growth is driven by the rapid rise in the geriatric. The high number of rural inhabitants who experience greater exposure to fertilizer chemicals and better and quicker diagnostic techniques are likely to increase the number of hairy cell leukemia treatment patients.

Increase in diagnosis rates will drive the market growth

According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect hairy cell leukemia. The first and foremost diagnostic test is a complete blood profile which indicates the total number of lymphocytes, which indicates the disease. Physicians can quickly diagnose if there is an enlarged spleen by physical examination. One important confirmation test is the presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. The diagnosis rate of hairy cell leukemia has increased during the last two decades, which is expected to drive the market in the forecast period.

The persence of professional consultant hematologist is driving the market growth

The persence of professional consultant hematologists in the ruler and urban areas of developing developed and underdeveloped regions drive the global hairy cell leukemia market. The presence of diagnostic centers that play a vital role in detecting various types of leukemia is driving the market growth. The high number of rural inhabitants who experience greater exposure to fertilizer chemicals and better and quicker diagnostic techniques are likely to increase the number of hairy cell leukemia treatment patients.

Lack of awareness about such malignancies will hamper the market

However, lack of awareness about such malignancies and low efforts in research and development of novel treatment in hairy cell leukemia treatment is expected to restrain the market during the forecast period.

Treatment may not be required for people in the beginning stages of hairy cell leukemia. Because this cancer advances very gradually and sometimes doesn't progress at all, medication is often recommended only after signs and manifestations develop. The majority of patients with hairy cell leukemia eventually require treatment in the later stages. This factor will hamper the market growth.

COVID-19 Impact Analysis

The Hairy Cell Leukemia Foundation has recently gathered experts and discussed different clinical strategies for the supervision of COVID patients. The new recommendations modify the diagnosis and management of Hairy Cell Leukemia to the contemporary COVID-19 pandemic. A recent survey of the clinical course of patients with chronic lymphocytic leukemia who have COVID-19 reveals the high mortality linked with the need for hospitalization, improved patient age, and the number of co-morbid conditions.

At present, there are no renewed published data on the disease rates with COVID in Hairy Cell Leukemia patients. Experiences with the course of COVID-19 in Hairy Cell Leukemia patients are limited to case reports and individual communications. Despite this lack of evidence, Hairy Cell Leukemia patients and their treating physicians ask for guidance.

Segment Analysis

By therapy, the hairy cell leukemia Market is classified into targeted therapy, radiation therapy, immunotherapy, chemotherapy.

On the basis of therapy, the hairy cell leukemia Market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.

The chemotherapy segment are expected to dominate the hairy cell leukemia Market during the forecast period

As per the American Cancer Society, there was throughout 22,840 death from hairy cell leukemia in 2019. Many companies focus on expanding breakthrough products to treat hairy cell leukemia to maintain their competing advantage and enter new regional markets. Chemotherapy drugs, especially purine analogs such as cladribine and pentostatin, are recognized as an initial treatment choice for most people with hairy cell leukemia. Additionally, the increase in funding for companies included in the research related to hairy cell leukemia is expected to drive the market growth in the forecast period.

Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Geographical Analysis

North America region holds the largest market share in the global Hairy Cell Leukemia Market

North America region is dominating the global hairy cell leukemia market accounted for the largest market share in 2020, owing to the high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer that affects about 6,000 persons in the United States.

The 2% of all hairy cell leukemia, with approx. 1000 new cases being recorded in the U.S each year. In the United States, a higher frequency of hairy cell leukemia is seen among white Americans than between African-Americans or Asians. Now a day next-generation sequencing is a gaining field in biomedical and healthcare research. This growing technology gives the roadmap for the researchers in the drug discovery and development of the hairy cell leukemia disorder.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

Competitive Landscape

The hairy cell leukemia market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis Inc, Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and Celgene Corporation among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hairy cell leukemia market globally.

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Why Purchase the Report?

  • Visualize the composition of the hairy cell leukemia market segmentation by therapy, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in hairy cell leukemia market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of hairy cell leukemia market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Hairy Cell Leukemia Market report would provide an access to an approx. 69 market data table, 65 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Hairy Cell Leukemia Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Hairy Cell Leukemia Market - Market Definition and Overview

3. Global Hairy Cell Leukemia Market - Executive Summary

  • 3.1. Market Snippet by Therapy
  • 3.2. Market Snippet by End User
  • 3.3. Market Snippet by Region

4. Global Hairy Cell Leukemia Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in diagnosis rates will drive the market growth
      • 4.1.1.2. The presence of professional consultant hematologist is driving the market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness about such malignancies will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Hairy Cell Leukemia Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Hairy Cell Leukemia Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Hairy Cell Leukemia Market - By Therapy

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 7.1.2. Market Attractiveness Index, By Therapy
  • 7.2. Targeted Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Immunotherapy
  • 7.4. Radiation Therapy
  • 7.5. Chemotherapy

8. Global Hairy Cell Leukemia Market - By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Clinics
  • 8.4. Ambulatory Surgical Centers

9. Global Hairy Cell Leukemia Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Global Hairy Cell Leukemia Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Global Hairy Cell Leukemia Market- Company Profiles

  • 11.1. Amgen Inc. *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. AstraZeneca PLC
  • 11.3. Bayer AG
  • 11.4. Celgene Corporation
  • 11.5. Eli Lilly
  • 11.6. Bristol-Myers Squibb Company
  • 11.7. Gilead Sciences, Inc.
  • 11.8. Takeda Pharmaceutical Company Limited
  • 11.9. Daiichi Sankyo Company, Limited
  • 11.10. UCB SA

LIST NOT EXHAUSTIVE

12. Global Hairy Cell Leukemia Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us